Levenue 750 Tablet contains Levetiracetam 750 mg, an antiepileptic medication indicated for the treatment of partial-onset seizures, myoclonic seizures, and primary generalized tonic-clonic seizures in adults and pediatric patients. Levetiracetam acts by modulating synaptic neurotransmitter release through binding to the synaptic vesicle protein SV2A, thereby reducing neuronal excitability and seizure propagation. This medication is commonly prescribed as monotherapy or adjunctive therapy for epilepsy management. Levenue 750 Tablet is well-absorbed orally, with rapid onset of action and minimal drug interactions, making it suitable for long-term use. Dosage should be individualized based on patient response and tolerability, with gradual titration to minimize adverse effects. Common side effects include somnolence, dizziness, headache, and fatigue, while serious adverse reactions such as behavioral changes or hypersensitivity are rare but warrant prompt medical attention. Caution is advised in patients with renal impairment, and dose adjustments may be necessary. Levenue 750 Tablet should be used under strict medical supervision, with regular monitoring to optimize therapeutic outcomes and minimize risks. It is essential to adhere to prescribed regimens and not discontinue therapy abruptly to prevent seizure exacerbation.